Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| AOD-9604 | Tesamorelin | |
|---|---|---|
| Category | Growth Factors | Peptides |
| Standard Dose | Research indicates 250-300 mcg daily via subcutaneous injection, administered in the morning on an empty stomach. | Research indicates 2 mg administered once daily via subcutaneous injection (FDA-approved dose for HIV lipodystrophy). |
| Timing | Morning administration on empty stomach, at least 30 minutes before eating. Fasted state enhances lipolytic effect. | Morning administration on empty stomach. Consistent daily timing recommended. |
| Cycle Duration | 12-20 week cycles. | 26+ weeks in clinical trials. Long-term use is common; effects are not sustained after discontinuation. |
| Evidence Level | moderate_human | Strong (FDA-approved indication), Moderate (longevity) |
AOD-9604 is a synthetic 16-amino acid fragment (residues 176-191) of the C-terminal domain of human growth hormone with a tyrosine substitution at the N-terminus. It selectively stimulates lipolysis by upregulating beta-3 adrenergic receptors in adipose tissue while inhibiting lipogenesis. It modulates lipid and glucose metabolism through beta-adrenergic and AMPK-related pathways without influencing IGF-1 activity, growth, or insulin sensitivity — retaining GH's fat-burning properties without its growth-promoting effects.
Research indicates 250-300 mcg daily via subcutaneous injection, administered in the morning on an empty stomach.
Morning administration on empty stomach, at least 30 minutes before eating. Fasted state enhances lipolytic effect.
12-20 week cycles.
Tesamorelin is an FDA-approved synthetic 44-amino acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminal tyrosine that confers resistance to DPP-IV degradation. It binds GHRH receptors on anterior pituitary somatotrophs, stimulating endogenous GH production and secretion while maintaining pulsatile release patterns. Tesamorelin selectively reduces visceral adipose tissue (15-20% reduction in trials) while preserving subcutaneous fat, and markedly increases plasma GH and IGF-1 levels with once-daily dosing.
Research indicates 2 mg administered once daily via subcutaneous injection (FDA-approved dose for HIV lipodystrophy).
Morning administration on empty stomach. Consistent daily timing recommended.
26+ weeks in clinical trials. Long-term use is common; effects are not sustained after discontinuation.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →